Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to ...

IgAN research, focusing on real-world patient experiences, reveals unmet needs in disease education, affordability, and care navigationEXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global ...

The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

FDA grants accelerated approval for Novartis's Vanrafia (atrasentan) for IgA nephropathy. The drug joins Tarpeyo and Filspari as well as Novartis' own Fabhalta in treating this rare kidney disease.

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

The FDA has granted accelerated approval to Novartis’ Vanrafia for adults with primary immunoglobulin A nephropathy (IgAN).

IgAN is a progressive, rare kidney disease in which the immune system attacks the kidneys, often causing glomerular ...

Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...